Organization
Durham, NC
29 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Association between rare pathogenic variants in established cancer risk genes and the diagnosis of single and multiple common cancers: A UK Biobank study.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers and Department of Medicine, Duke University School of Medicine, Durham, NC, NorthShore University HealthSystem Research Institute, Evanston, IL,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples.Org: NeoGenomics Laboratories, Inc., Aliso Viejo, CA, Durham, NC, Fort Myers, FL, San Diego, CA,
Abstract
Quality of telehealth-provided cancer care in VA.Org: Duke University Medical Center, Durham, NC, Durham VA Medical Center, Michigan State University College of Human Medicine, East Lansing, MI,
Abstract
A new model to enhance enrollment of diverse participants to therapeutic clinical trials.Org: Golgi, Inc, Lexington, KY, Boston, MA, Yale Cancer Center, Yale School of Medicine,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Chicago Pritzker School of Medicine, Fox Chase Cancer Center, University of Pennsylvania, Columbia University Mailman School of Public Health, New York, NY, Duke University Medical Center,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Unstructured EMR data hold the key to oncology studies: Methods for validating NLP-extracted phenotypes from EMR notes.Org: IQVIA, Boston Pharmaceuticals, MaaT Pharma, South Bend, Intercept Pharmaceuticals,
Abstract
Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Buffalo, NY, Durham, NC, Burlington, NC,
Abstract
Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, ASCO, Alexandria, VA,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, Yale Cancer Center, Yale School of Medicine, New Haven, CT, New Haven, CT,
Abstract
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Moffitt Cancer Center, Tampa, FL,
Abstract
Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.Org: Duke Cancer Institute, Durham, NC, Durham VA Medical Center, VA National Precision Oncology Program, VA National Oncology Program Office,
Abstract
Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Durham, NC,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,
Abstract
FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients.Org: Tempus Labs, Inc., Durham, NC, Statagize LLC, Thousand Oaks, CA, Indapta Therapeutics Inc.,
Abstract
Barriers and facilitators to implementing the Veterans Health Administration National Teleoncology Service: A qualitative descriptive study.Org: Durham VA Medical Center, Duke University Medical Center, Durham, NC, VA National Oncology Program and Durham VA Medical Center, Durham VA Health Care System,